Bifogade filer
Dr. Janet Hoogstraate new board member of AlzeCure Pharma
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that Janet Hoogstraate is newly elected to AlzeCure's board.
Dr Janet Hoogstraate has many years’ experience in life science, with leading roles at Astra Zeneca, among others. She has a PhD in Biopharmaceutical Sciences from the University of Leiden in the Netherlands and an eMBA from Hult International Business School. Janet has a great interest and knowledge in neuroscience research and has been, among other things, chairman of the board of the Stockholm Brain Institute. Janet is today CEO of Valneva Sweden AB, and her extensive experience in preclinical research, the pain area and biotech will be a great asset for AlzeCure.
”We are very pleased to have Janet join the board. Her expertise in neuroscience and extensive experience in driving preclinical research and development will further strengthen us,” said AlzeCure’s chairman Thomas Pollare.
”I am very pleased to join the board of AlzeCure Pharma with its highly skilled and motivated team and its exciting portfolio of projects in key areas of great medical need. I look forward to contributing my experience in the field of neuroscience, particularly with respect to early development, as well as from regulatory registrations at various stages of development; all to support AlzeCure to further success,” said Janet Hoogstraate.